NCT03666000: A trial that was reported late by Imugene Limited
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT03666000 |
|---|---|
| Title | Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 11, 2019 |
| Completion date | March 31, 2024 |
| Required reporting date | March 31, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 28, 2024 |
| Days late | None |